Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 403

Sort by

Sort Order Select

Journal Articles

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18

Blood blood.2025031006.

https://doi.org/10.1182/blood.2025031006

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal evolution of pediatric Acute Myeloid Leukemia

Masayuki Umeda, Pandurang Kolekar, Anna Huskey, Shruthi Suryaprakash, Hanxia Li, Tamara Westover, Jing Ma, Mike Walsh, Guangchun Song, Yanling Liu, Quang Tran, Seth Karol, Hiroto Inaba, Jeffrey Rubnitz, Raul Ribeiro, Xiaotu Ma, Jeffery Klco

Blood (2025) 146 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2025-1721

Published: 2025

Journal Articles

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Blood (2025) 146 (Supplement 1): 4052.

https://doi.org/10.1182/blood-2025-4052

Published: 2025

Journal Articles

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Mike Dennis, Jad Othman, Joanna Canham, Ian Thomas, Sean Johnson, Nick Telford, Beth Harrison, Jeyaprakash Ramachandran, James Cavenagh, Claire Arnold, Claus Marcher, Richard Kelly, Mhairi Copland, Alan Burnett, Richard Dillon, Nigel Russell

Blood (2025) 146 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2025-3435

Published: 2025

Journal Articles

primary breast lymphoma: A 10-year retrospective case series on clinical features, diagnostic imaging, and outcomes from a diverse population treated at mount sinai medical center in miami beach

Carla Romagnoli, Leily Santos-Carrion, Alexandra Lyubimova, Evelyn Goya Balaguer, Oleg Gligich, Michael Schwartz, Mike Cusnir, Jacqueline Barrientos

Blood (2025) 146 (Supplement 1): 8105.

https://doi.org/10.1182/blood-2025-8105

Published: 2025

Journal Articles

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Jing-Zhou Hou, Tejvir Singh, Wesley Falconer, Patrick Travis, Olalekan Ajayi, Jason Stinnett, Kyle Kitchen, Anna Rui, Mike Gart, Lisa Kunst, Lindsay Aton, Poras Dave, Doug Kanovsky, Brandon Wang, Prateesh Varughese, Robert Geller, Jeffrey Scott, Rushir Choksi

Blood (2025) 146 (Supplement 1): 7934.

https://doi.org/10.1182/blood-2025-7934

Published: 2025

Journal Articles

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Blood (2025) 146 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2025-6286

Published: 2025

Journal Articles

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Rushir Choksi, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Taral Patel, Fred Kudrik, Tejvir Singh, Steven Champaloux, John Li, Anna Rui, Gino Cioffi, Don Parris, Mike Gart, Janet Donegan, Lisa Morere, Lisa Kunst, Lindsay Aton, Jeffrey Scott, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 6285.

https://doi.org/10.1182/blood-2025-6285

Published: 2025

Journal Articles

Results from the first 200 ordered clinical modified ham (mHam) functional complement tests

Bradley Lewis, Jamey Kain, Gayatri Raghuraman, Connie Ng, Bjorn Stromsness, Mike Ero

Blood (2025) 146 (Supplement 1): 1323.

https://doi.org/10.1182/blood-2025-1323

Published: 2025

Journal Articles

Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study

Blood (2025) 146 (Supplement 1): 346.

https://doi.org/10.1182/blood-2025-346

Published: 2025

Journal Articles

FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials

Blood (2025) 146 (Supplement 1): 345.

https://doi.org/10.1182/blood-2025-345

Published: 2025

Journal Articles

Mass spectrometry-based molecular investigation identifies key proteins involved in synergistic AXL and BCL-2 dual inhibition for Acute Myeloid Leukemia

Hongyu Guo, Aicha Houfani, Yuming Shi, Hong Zhang, Mike Lyle, Jun Yan, Zaihui Zhang, Leonard Foster, Xiaoyan Jiang

Blood (2025) 146 (Supplement 1): 6789.

https://doi.org/10.1182/blood-2025-6789

Published: 2025

Journal Articles

Estimating the United States cure-adjusted prevalence of diffuse large B-cell lymphoma (DLBCL): An epidemiological model

Mahmoud Hashim, Tara Beaulieu, Jackie Kwong, Jacqueline Bussolari, Mike Spencer, Maren Gaudig

Blood (2025) 146 (Supplement 1): 1885.

https://doi.org/10.1182/blood-2025-1885

Published: 2025

Journal Articles

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Mike Gart, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6317.

https://doi.org/10.1182/blood-2025-6317

Published: 2025

Journal Articles

Characterizing the In Vivo impact of inflammation on Samd9l hematopoietic phenotypes.

Melvin Thomas, Emily Xiong, Tamara Westover, Mike Walsh, Jing Ma, Chandra Rolle, Yonghui Ni, Steven Burden, Laura Janke, Stanley Pounds, Jeffery Klco

Blood (2025) 146 (Supplement 1): 2055.

https://doi.org/10.1182/blood-2025-2055

Published: 2025

Journal Articles

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response

Jack Taylor-Stuart, Mark Ethell, Mike Potter, Sandra Easdale, Chloe Anthias, Caroline Furness, David Cunningham, Ian Chau, Dima El-Sharkawi, Sunil Iyengar, Emma Nicholson

Blood (2025) 146 (Supplement 1): 7134.

https://doi.org/10.1182/blood-2025-7134

Published: 2025

Journal Articles

Triglycerides, but not bilirubin or hemoglobin, can interfere with the modified ham (mHam) functional complement assay

James Anderson-Furgeson, Alex Aubrecht, Gayatri Raghuraman, Jamey Kain, Connie Ng, Bradley Lewis, Mike Ero

Blood (2025) 146 (Supplement 1): 6646.

https://doi.org/10.1182/blood-2025-6646

Published: 2025

Journal Articles

UBTF tandem duplications generate a nuclear export signal motif that drives an XPO1 dependency in leukemia

Blood (2025) 146 (Supplement 1): 986.

https://doi.org/10.1182/blood-2025-986

Published: 2025

Journal Articles

FLT3-F691L confers kinase-independent resistance via Grb2-dependent MAPK signaling in AML

LaQuita Jones, Akhtar Khadaroo, Riya Tiwari, Kwangmin Choi, Mike Adam, Mark Wunderlich, Cody Stillwell, Christina Sexton, William Seibel, Greg Tawa, Scott Hoyt, Craig Thomas, Daniel Starczynowski

Blood (2025) 146 (Supplement 1): 5049.

https://doi.org/10.1182/blood-2025-5049

Published: 2025

Journal Articles

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Rushir Choksi, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Taral Patel, Fred Kudrik, Tejvir Singh, Anna Rui, Gino Cioffi, Don Parris, Mike Gart, Janet Donegan, Lisa Morere, Lisa Kunst, Lindsay Aton, Poras Dave, Doug Kanovsky, Jeffrey Scott, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2025-4505

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18

Clonal evolution of pediatric Acute Myeloid Leukemia

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

primary breast lymphoma: A 10-year retrospective case series on clinical features, diagnostic imaging, and outcomes from a diverse population treated at mount sinai medical center in miami beach

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Results from the first 200 ordered clinical modified ham (mHam) functional complement tests

Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study

FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials

Mass spectrometry-based molecular investigation identifies key proteins involved in synergistic AXL and BCL-2 dual inhibition for Acute Myeloid Leukemia

Estimating the United States cure-adjusted prevalence of diffuse large B-cell lymphoma (DLBCL): An epidemiological model

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Characterizing the In Vivo impact of inflammation on Samd9l hematopoietic phenotypes.

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response

Triglycerides, but not bilirubin or hemoglobin, can interfere with the modified ham (mHam) functional complement assay

UBTF tandem duplications generate a nuclear export signal motif that drives an XPO1 dependency in leukemia

FLT3-F691L confers kinase-independent resistance via Grb2-dependent MAPK signaling in AML

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only